Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ced/llae017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recalcitrant Pustular Dermatosis Successfully Treated With Prolonged Isotretinoin Therapy.
Cureus
November 2024
Dermatology, Imperial Dermatology, Hollywood, USA.
Isotretinoin (13-cis-retinoic acid) is a well-established systemic treatment for moderate to severe acne vulgaris, renowned for its ability to target multiple contributors to acne pathogenesis. However, its therapeutic potential extends beyond conventional acne management. This case report highlights its efficacy in treating recalcitrant pustular dermatosis, a condition that proved resistant to standard therapies and posed significant diagnostic challenges.
View Article and Find Full Text PDFSerum Catestatin Levels in Patients with Acne Vulgaris: Single-Center Prospective Study.
Skin Appendage Disord
December 2024
Department of Dermatology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Introduction: Recent studies showed that antimicrobial peptides have an essential role in the pathogenesis of acne vulgaris. This study aims to investigate serum catestatin levels in acne vulgaris patients and focuses on the change in serum levels after systemic isotretinoin therapy.
Methods: This prospective study includes 101 acne vulgaris patients and 28 healthy controls.
Keloid Formation and Any Skin Complications in Patients Treated With Isotretinoin and Undergone Any Skin-Related Procedures.
J Cosmet Dermatol
November 2024
Department of Dermatology, Rasool Akram Medical Complex Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Background: Isotretinoin is widely used for moderate to severe acne vulgaris. Despite its broad application, isotretinoin carries a risk of permanent scarring and keloid formation following various skin procedures. As a result, a delay of at least 6-12 months after completing or discontinuing isotretinoin treatment is commonly recommended before undergoing skin procedures.
View Article and Find Full Text PDFManagement of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.
J Eur Acad Dermatol Venereol
October 2024
Oncodermatology Department, Cancer University Institute, Toulouse Oncopole, Toulouse, France.
Background: There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists.
Objective: To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus.
Methods: The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force 'Dermatology for Cancer Patients' who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia.
From drug therapy failures to laser therapy victory: A case report and literature review of lupus miliaris disseminatus faciei resolution.
Clin Case Rep
September 2024
Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine Iran University of Medical Sciences (IUMS) Tehran Iran.
Article Synopsis
- Pulsed dye laser (PDL) treatment has shown effectiveness in resolving lupus miliaris disseminatus faciei (LMDF) in cases where drug therapies have been unsuccessful.
- A 28-year-old male with persistent facial eruptions confirmed as LMDF received PDL after failed treatments with isotretinoin and methotrexate, leading to significant improvement without scarring.
- Early intervention with PDL may enhance treatment outcomes and reduce the risk of disease relapse, indicating the need for further research on laser therapy's role in managing LMDF.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!